FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Clinical trials for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) explained in plain language.
Never miss a new study
Get alerted when new FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) trials appear
Sign up with your email to follow new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for halting rogue bone growth in rare disease
Disease control Recruiting nowThis study is observing whether existing anti-inflammatory drugs (anakinra or canakinumab) can help control severe FOP, a rare genetic disorder that causes muscle and soft tissues to turn into bone. Researchers will follow 11 patients, aged 6-30, who have very frequent painful fl…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New hope for 'Stone man Syndrome': trial tests drug to halt extra bone growth
Disease control Recruiting nowThis study is testing whether an investigational drug called INCB000928 can slow or stop the formation of new, abnormal bone in people with fibrodysplasia ossificans progressiva (FOP), a rare and severe genetic disorder. About 98 participants, including children as young as 2, wi…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC